Table 3.

Clinical parameters and outcomes for children with lymphadenitis, stratified by severity

	Uncomplicated disease	Complicated disease	p
	n = 123	n = 25
Days from admission to defervescence, mean (SD)	1.6 (1.2)	1.9 (1.7)	0.383
Length of stay (days), mean (SD)	3.5 (2.1)	5.5 (2.7)	< 0.001 a
Duration of antibiotics used, mean (SD)
Total duration antibiotics	9.7 (3.4)	13.5 (5.8)	< 0.001
Duration IV antibiotics	3.7 (2.2)	5.1 (2.8)	0.007
Duration oral antibiotics	6.1 (2.7)	8.4 (4.2)	< 0.001
Antibiotic timing (number of days from admission to initiation), mean (SD)	0.1 (0.6)	0.1 (0.3)	0.824
Adverse events, n (%)	4/123 (3.3)a	1/25 (4.0)b	0.852
Change of medication due to AE, n (%)	3/4 (75.0)c	0/1 (0.0)	0.272
Surgery performed, n (%)	10/123 (8.1)	14/25 (56.0)	< 0.001
Surgical complications, n (%)	0/10 (0.0)	0/14 (0.0)	-
ID consult performed, n (%)	11/123 (8.9)	4/25 (16.0)	0.290
Intensive care unit admission, n (%)	0/123 (0.0)	0/25 (0.0)	-
Representation within 30 days, n (%)	5/123 (4.1)	1/25 (4.0)	0.988

^a Vomiting/did not tolerate (clindamycin) (2 patients); did not tolerate (augmentin) (1 patient); rash (cephalexin) (1 patient)

^b Rash (augmentin)

^c Vomiting/did not tolerate (clindamycin) (2 patients); did not tolerate (augmentin) (1 patient)